Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
News|Videos|January 23, 2025
Examples of Quality of Life Improvement for Patients With Tardive Dyskinesia
Author(s)Erin Crown, MHS, PA-C, Psych-CAQ
Key Takeaways
- Erin Crown highlighted significant quality of life improvements in patients treated for tardive dyskinesia, emphasizing their meaningful impact.
- Crown is a psychiatric physician assistant and principal investigator in clinical trials, managing Oasis LifeCare and Future Options Research.
Check out 2 high-level examples of patient quality of life improvement following treatment for tardive dyskinesia.
Advertisement
CONFERENCE REPORTER
Erin Crown, MHS, PA-C, Psych-CAQ, shared 2 high-level examples of patient improvements after treatment for tardive dyskinesia with Psychiatric Times at the Real Psychiatry conference.
"These are about quality of life," said Crown. "They are meaningful."
What improvement have you seen in your patients with tardive dyskinesia? Want to share a case composite? Email us at
Ms Crown is a psychiatric physician assistant in State College, PA. She is the owner and managing member of Oasis LifeCare, the owner of Future Options Research, and principal investigator in clinical trials.
Advertisement
Related to this article
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Learn how to prevent and spot tardive dyskinesia from antipsychotics, track key risk factors, and treat symptoms with VMAT2 inhibitors.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psychiatric Pipeline in Review: Quarter 3, 2026
2
VA Expands Informed Consent Requirements for Psychotropic Medications Starting in 2027
3
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
4
September 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
5